Clinical Laboratory COVID-19 Response Call Monday, April 27, 2020 at 3:00 PM EDT

• Welcome

- Jasmine Chaitram, CDC Division of Laboratory Systems
- Diagnostic and Serology Testing: Addressing Problems and Challenges
 - Carmen L. Wiley, President, AACC
- Serology Testing Available at Quest Diagnostics
 - Ann Salm, Quest Diagnostics
- LabCorp Pixel Home Self-Collection Overveiw
 - Brian Krueger, LabCorp
- Laboratory Biosafety Update
 - Bill Arndt, CDC Division of Laboratory Systems
- Update on Serology Testing, Point-of-Care Testing, and Laboratory Data Harmonization
 - Tim Stenzel and Sara Brenner, U.S. Food and Drug Administration (FDA)

To Ask a Question

- Using the Webinar System
 - Click the Q&A button in the Zoom webinar system
 - Type your question in the Q&A box
 - Submit your question
 - Please do not submit a question using the chat button

For media questions, please contact CDC Media Relations at <u>media@cdc.gov</u>.

Center for Surveillance, Epidemiology, and Laboratory Services

Diagnostic and Serology Testing: Addressing Problems and Challenges

Carmen Wiley, PhD, DABCC ACCC President



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Diagnostic Testing: Ongoing Problems

- Access to supplies
 - Collection, assay components, PPE
- Access to equipment
 - Analyzers, cartridges/reagents
- Coordination of resources
 - Labs competing for same materials



Diagnostic Testing: Ongoing Problems

- Staffing
 - Too few trained personnel for tasks
- Finances
 - Costs high, revenues declining
- Provider education
 - Clearer understanding needed of different tests



Serology Testing – The Challenges We Face

- Need for serological testing
 - IgM, IgG, IgA post-infection
 - Sub-clinical or mild infection
 - Surveillance and research



Serology Testing – The Challenges We Face

- Several serological tests developed/in-process
 - Sensitivity/specificity
 - Qualitative/quantitative
 - Cross reactivity
 - Aggressive vendors/unreliable serological tests



What AACC is Doing

- On serology:
 - CA State Taskforce
 - Taskforce developing serology testing guide
- More generally:
 - <u>Resource site</u>
 - Discussion forum
 - Directory



Better health through laboratory medicine.



Thank you. **Questions?**

Center for Surveillance, Epidemiology, and Laboratory Services

Serology Testing Available at Quest Diagnostics

Ann Salm, Quest Diagnostics



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Quest Diagnostics – Useful Links

Quest COVID-19 Web Page: https://www.questdiagnostics.com/home/Covid-19/

*For questions, email <u>COVID19@QuestDiagnostics.com</u>

Quest Press Release for Serology Testing: <u>https://questdiagnostics.sharepoint.com/sites/DigitalWorkplace/News/Pages/Quest-begins-to-perform-COVID-19-antibody-testing.aspx</u>

Quest Serology Frequently-Asked Questions: <u>http://education.questdiagnostics.com/faq/FAQ219</u> Center for Surveillance, Epidemiology, and Laboratory Services

LabCorp Pixel Home Self-Collection Overview

Brian Krueger, LabCorp



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

SLabCorp*


LabCorp COVID-19 RT-PCR Test

Qualitative RT-PCR Test

- ✓ High Throughput Implementation of CDC Assay
 - o EUA Granted March 16, 2020
 - o Amended and approved as a multiplex assay April 14, 2020

✓ Assay Specifics

- Multiplexed by changing probe dyes
 - o N1-FAM
 - o N2-Yakima Yellow
 - Rnase P Cy5
 - N3 dropped as an assay target at the recommendation of FDA and CDC
- o 100% Sensitivity and Specificity on multiplex validation Clinical Samples
- o Tested against 26 potentially interfering respiratory organisms
- o LOD of 6.25 cp/uL (from extraction)
- ✓ Approved for the detection of COVID-19 in symptomatic patients



Pixel Self-Collection Testing

SLabCorp[®]



Validation Overview



Stability Study

- ✓ Experimental Design
 - 20 positives and 20 negatives
 - o Ohr, 24hr RT, 72hr 2-8C
 - Positives spiked with 1e3cp/uL virus to a final concentration of 10 cp/uL
 - No degradation of expected Ct over the time-course
 - No False Positives or False Negatives

	N	N1		N2		RP	
	Mean	STDEV	Mean	STDEV	Mean	STDEV	
0hr 10cp/uL (20)	34.94719	1.107074	34.8628	1.471946	31.26584	1.2432	
24hr 10cp/uL (20)	34.96442	0.445445	34.86464	0.642225	31.96352	1.559504	
96hr 10cp/uL (20)	35.00282	0.341642	35.55211	0.928614	31.64471	0.928614	

Validation Overview



Temperature Excursion Study

✓ Experimental Design

- 20 positives and 20 negatives
- Positives spiked with 1e3cp/uL virus to 10 cp/uL final concentration
- Cycled in an oven to replicate "worst case" shipping scenario

Temperature	Cycle Period	Cycle Period Hours	Total Time Hours
40°C	1	6	6
22°C	2	16	22
40°C	3	2	24
35°C	4	22	46
40°C	5	4	50

- No degradation of expected Ct over the 50hr time-course
- No False Positives or False Negatives

	N1		N2		RP	
	Mean	STDEV	Mean	STDEV	Mean	STDEV
50hr Excursion 10cp/uL (20)	31.66844	1.465225	33.84067	2.06126	26.4825	2.702494


Validation Overview



Self-Collect and Shipping Study

✓ Experimental Design

- o 30 lay participants collected 2 samples (tubes) each
- o 30 tubes spiked with clinical positives
- Shipped via FedEx to the lab (72hr transit time)
- No degradation of expected Ct over the time-course
- No False Positives or False Negatives





{Improving Health, Improving Lives }

For Internal Use Only-Not for Distribution

Center for Surveillance, Epidemiology, and Laboratory Services

Laboratory Biosafety Update for COVID-19

Bill Arndt, PhD CDC Division of Laboratory Systems



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Biosafety Resources

COVID-19 Information for Laboratories page: https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html

Interim Laboratory Biosafety Guidelines: <u>https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html</u>

Laboratory Biosafety Frequently Asked Questions: <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/biosafety-faqs.html</u>

Send Inquiries to: DLSInquiries@cdc.gov

CDC Information for Laboratories

Interim Guidance for Collecting, Handling, and Testing Clinical Specimens <u>https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html</u>

Diagnostic Tools and Virus <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/tool-virus-requests.html</u>

Emergency Preparedness for Laboratory Personnel https://emergency.cdc.gov/labissues/index.asp

CDC's Laboratory Outreach Communication System (LOCS) https://www.cdc.gov/csels/dls/locs/

Center for Surveillance, Epidemiology, and Laboratory Services

FDA Agenda Item

Tim Stenzel, MD, PhD Sara Brenner, MD, MPH U.S. Food and Drug Administration (FDA)



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Food and Drug Administration (FDA)

COVID-19 Emergency Use Authorization (EUA) Information: <u>https://www.fda.gov/medical-devices/emergency-situations-</u> <u>medical-devices/emergency-use-authorizations</u>

COVID-19 Frequently Asked Questions: <u>https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/coronavirus-disease-2019-covid-19-frequently-asked-questions</u>

COVID-19 Updates: <u>https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#2019-ncov</u>

Food and Drug Administration (FDA)

COVID-19 Diagnostic Development: <u>CDRH-EUA-Templates@fda.hhs.gov</u>

Spot Shortages of Testing Supplies: 24 hour support available

- 1. Call 1-888-INFO-FDA (1-888-463-6332)
- 2. Then press star (*)

CDC Social Media



Facebook: <u>https://www.facebook.com/CDC</u>



Twitter: https://twitter.com/cdcgov



LinkedIn: <u>https://www.linkedin.com/company/cdc</u>

Thank You For Your Time!

Photo submitted by the Microbiology Laboratory at The University of Pittsburgh Medical Center.

-this box being opened by an American Hero # love the Lab # lab professionals rock